Mihaela-Graziela Bradu @Grazi3la: "Espresso News ☕ 💊 Johnson &..."

Romania

Espresso News ☕ 💊 Johnson & Johnson is back in the spotlight for investors after new positive signals from the pharmaceutical sector. The company recently received major approvals for treatments targeting autoimmune diseases and continues to expand its global drug portfolio. At the same time, the 2026 financial results showed solid sales and stable demand for its medical products. In a period when many healthcare companies are hit by pressures and competition, $JNJ (Johnson & Johnson) is trying to send a simple message to the market, stability, dividends, and constant investment in new treatments. ❓ Would you have the patience to hold Johnson & Johnson in your portfolio for another 5 years? $ABBV (AbbVie Inc) $MRNA (Moderna Inc) $SAN.PA (Sanofi) $ISRG (Intuitive Surgical Inc) $VRTX (Vertex Pharmaceuticals Incorporated)

Not investment advice. The author may have financial interests in the mentioned instruments.